Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CPHI, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
CPHI holds $304,874 in cash and short-term investments (as of Jun 30, 2026) and burns about $44,060/quarter from operations, an estimated runway of 20.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 23 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CPHI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Tao (Chengdu) Liu 10% owner |
Insider | 15,000,000 | 34.87% | 2023-12-28 |
Share count 43,022,002 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CPHI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →